Biophytis SA submitted an IND for a Phase 2 OBA study on obesity using BIO101 to the US FDA.

Biophytis SA, a clinical-stage biotech company, submitted an IND application to the US FDA for its Phase 2 OBA clinical study on obesity using BIO101 (20-hydroxyecdysone). The study will evaluate effectiveness and safety in obesity and overweight patients with secondary comorbidities, treated with GLP-1 receptor agonists and hypocaloric dieting. The primary objective is to measure improvements in lower limb muscle strength, with secondary endpoints exploring mobility.

June 10, 2024
3 Articles

Further Reading